Donald Fong

Company: Annexon Biosciences

Job title: Vice President, Ophthalmology Clinical Development

Seminars:

Spotlight on ANX007 – Inhibition of C1q for GA 11:45 am

Discuss rationale for chronic classical complement activation as a driver of GA Assess potential advantages of selective, local inhibition of C1q for regulating complement activity in GA Review Phase 1 safety and target engagement with ANX007 Provide update on ARCHER, the ongoing Phase 2 study of ANX007 in GARead more

day: Track 2 Day 1 AM